Does Dr. MELIKA ABDULWHAB have financial conflicts of interest?

Dr. MELIKA ABDULWHAB (MD) has received a total of $149 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $149 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MELIKA ABDULWHAB?

According to CMS Open Payments data, Dr. MELIKA ABDULWHAB received funding from NOVARTIS PHARMACEUTICALS CORPORATION ($44), NOVO NORDISK ($35), and BIOHAVEN PHARMACEUTICAL HOLDING COMPANY ($19).

Does Dr. MELIKA ABDULWHAB receive research grants or speaking fees?

Dr. MELIKA ABDULWHAB has received $149 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. MELIKA ABDULWHAB

MDReal-Time Hydrated

Specialty: Nurse Practitioner, Primary Care

Practice Location: MINNETONKA, MN 55343

NPI Number: 1538662515

LIFETIME INDUSTRY VALUE

$149

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ABDULWHAB is a verified Nurse Practitioner, Primary Care practitioner based in MINNETONKA, MN.

Between 2021 and 2024, Dr. ABDULWHAB had an overall industry promotional and research financial footprint of $149 as recorded in the federal CMS Open Payments database.

$149 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABDULWHAB's primary funding source is NOVARTIS PHARMACEUTICALS CORPORATION, which accounts for $44 (representing 29.3% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 1

$44

29.3%

NOVO NORDISK

Rank 2

$35

23.5%

BIOHAVEN PHARMACEUTICAL HOLDING COMPANY

Rank 3

$19

12.8%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.